Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.98 USD
-0.05 (-2.46%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRDL 1.98 -0.05(-2.46%)
Will CRDL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
5 Small Drug Stocks to Buy From a Recovering Industry
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for CRDL
Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
Cardiol Therapeutics Inc.: Financial Update
Cordel Group Awards Stock Options to CRO
AIM WINNERS & LOSERS: UK Oil & Gas falls on GBP1 million fundraise